Keywords
Lenalidomide combined with cyclophosphamide and dexamethasone
Conventional treatment
Clinical efficacy
Submitted : 2022-04-30
Accepted : 2022-05-15
Published : 2022-05-30
Abstract
Objective: Multiple myeloma has a great impact on patients; the use of implant denture restorative treatment is ideal, and it is vital to carry out scientific treatment methods. Methods: The research subjects were inclusive of 60 patients with multiple myeloma, who were randomly selected from January 2019 to December 2019. The patients were divided into a study group and a control group, with 30 patients in each group. The patients in the control group were treated with conventional treatment, while the patients in the study group were treated with lenalidomide combined with cyclophosphamide and dexamethasone. The effectiveness of treatment, adverse effects, and clinical indices of the two groups were compared. Results: Comparing different treatment methods, the differences in the indices between the two groups were statistically significant (p < 0.05). Conclusion: The use of lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of patients with multiple myeloma increases the effectiveness of treatment and improves patients’ clinical indices; thus, it is worthy of promotion.
References
Jing L, Lan XJ, 2020, Efficacy and Safety of Lenalidomide Combined with Low-Dose Dexamethasone in the Treatment of Multiple Myeloma in the Elderly. Primary Care Forum, 24(4): 492-493.
Wang J, Shang J, Jin S, et al., 2022, Efficacy Analysis of An All-Oral Regimen of Ixazomib in the Treatment of Relapsed Refractory Multiple Myeloma. Chinese Journal of Internal Medicine, 61(1): 95-98.
Fu B, Gu LH, Liu P, et al., 2021, Clinical Study on the Treatment of Relapsed Refractory Multiple Myeloma with An Isazomib-Based Chemotherapy Regimen. Leukemia & Lymphoma, 30(6): 340-343.
Gu SH, Yin SR, Zhao FX, et al., 2020, Bortezomib in Combination with Lenazepam. Efficacy of Bortezomib Combined with Lenalidomide and Dexamethasone in the Treatment of Multiple Myeloma. Journal of Aerospace Medicine, 31(11): 1353-1354.
Wang G, 2021, Analysis of the Effective Value of Applying Lenalidomide Combined with Low-Dose Dexamethasone in the Treatment of Relapsed Refractory Multiple Myeloma. Northern Pharmacology, 18(6): 125-126.
Lan M, Luo J, Li XJ, et al., 2021, Report of a Case of Autologous Peripheral Blood Stem Cell Transfusion for Anaphylaxis After Successful Retransfusion with Comprehensive Treatment. International Journal of Immunology, 44(4): 484-486.
Sun H, Du Y, Xu L, et al., 2020, Correlation of CD56 and CD117 Expression Levels with the Efficacy of Lenalidomide in the Treatment of Multiple Myeloma. Modern Biomedical Advances, 20(1): 72-75.
Wang Y, 2021, The Efficacy of Combining Bortezomib, Dexamethasone and Lenalidomide in the Treatment of Multiple Myeloma. Contemporary Medicine Series, 19(20): 109-111.
Wu C, Xu W, Huang L, et al., 2020, Efficacy and Safety Study of RVD Regimen for Multiple Myeloma. Internal Medicine Theory and Practice, 15(4): 251-256.
Zhao GX, Cheng Z, Wei RH, et al., 2021, A Case of Relapsed Refractory Multiple Myeloma Treated with Lenalidomide Combined with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells and Review of the Literature. Leukemia & Lymphoma, 30(4): 224-227.
Zhao W, Chen L, Wang L, et al., 2021, Efficacy Analysis of Modified VTD-PACE Regimen in the Treatment of Extramedullary Lesions and Plasma Cell Leukemia in Multiple Myeloma. Journal of Harbin Medical University, 55(1): 36-40.
Liu J, He HY, Li L, et al., 2021, Efficacy and Safety of Daratumumab for Relapsed/Refractory Multiple Myeloma. Chinese Journal of Hematology, 42(1): 27-32.
Lu P, 2020, Clinical Observation of Lenalidomide Combined with Cyclophosphamide and Low-Dose Dexamethasone in the Treatment of Multiple Myeloma. China Practical Medicine, 15(3): 145-146.
Liu S, Shang J, Lin Y, et al., 2021, Clinical Efficacy and Prognosis of Patients with Double-Hit High-Risk Multiple Myeloma. Chinese Journal of Oncology, 43(11): 1209-1214.
Jiang W, Luo P, 2021, Clinical Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma. Journal of Clinical Rational Drug Use, 14(21): 30-32.
Fan L, Ma YP, Zhang M, et al., 2020, Meta-Analysis of the Efficacy of Lenalidomide in the Treatment of Patients with Multiple Myeloma and Its Associated Serious Infections. International Journal of Blood Transfusion and Hematology, 43(1): 34-42.
Shi H, Wang HH, Liao AJ, 2020, Differential Expression of Chemokine CCL20 in Erlotuzumab- and Lenalidomide-Resistant Multiple Myeloma Cells. Modern Medical Oncology, 28(14): 2374-2377.
Yang Y, Xia Z, Zhang W, et al., 2021, Efficacy and Safety Analysis of Isazomib, Lenalidomide, and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma: A National Multicenter Real-World Study. Chinese Journal of Hematology, 42(8): 628-634.
Fan G, Wu P, Qu M, et al., 2020, Clinical Characteristics of Patients with Chronic Myeloid Leukemia Combined with Multiple Myeloma and Their Treatment. International Journal of Blood Transfusion and Hematology, 43(4): 318-324.
Wang Z, Li B, Li J, et al., 2021, Advances in the Application of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma. Shandong Medicine, 61(35): 101-104.